Ligand Pharmaceuticals, Inc. (LGND)
286.92
+2.65
(+0.93%)
USD |
NASDAQ |
Sep 02, 16:00
286.94
+0.02
(+0.01%)
After-Hours: 20:00
Ligand Pharmaceuticals Research and Development Expense (Annual) : 81.18M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 81.18M |
| December 31, 2024 | 21.42M |
| December 31, 2023 | 25.42M |
| December 31, 2022 | 36.25M |
| December 31, 2021 | 32.23M |
| December 31, 2020 | 57.12M |
| December 31, 2019 | 30.54M |
| December 31, 2018 | 27.86M |
| December 31, 2017 | 26.89M |
| December 31, 2016 | 21.22M |
| December 31, 2015 | 13.38M |
| December 31, 2014 | 12.12M |
| December 31, 2013 | 9.274M |
| December 31, 2012 | 10.79M |
| December 31, 2011 | 10.29M |
| December 31, 2010 | 22.07M |
| December 31, 2009 | 39.87M |
| Date | Value |
|---|---|
| December 31, 2008 | 30.77M |
| December 31, 2007 | 44.62M |
| December 31, 2006 | 41.93M |
| December 31, 2005 | 56.08M |
| December 31, 2004 | 65.20M |
| December 31, 2003 | 67.68M |
| December 31, 2002 | 58.81M |
| December 31, 2001 | 51.10M |
| December 31, 2000 | 35.09M |
| December 31, 1999 | |
| December 31, 1998 | |
| December 31, 1997 | |
| December 31, 1996 | |
| December 31, 1995 | |
| December 31, 1994 | |
| December 31, 1993 | 23.03M |
| December 31, 1992 | 13.37M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Johnson & Johnson | 14.83B |
| Eli Lilly & Co. | 13.34B |
| Merck & Co., Inc. | 12.51B |
| Zevra Therapeutics, Inc. | 12.55M |
| Liquidia Corp. | 38.45M |